Q/C Technologies, Inc. (QCLS): Cash & Equivalents
$987.0K
As of 2025-12-31
$307.6K
As of 2026-06-30
+9.6%
3-year compound annual growth
+46.1%
5-year compound annual growth
+9.4%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $987.0K | +470.0% | 2026-04-15, Balance as of period end |
| 2024-12-31 | $173.2K | -93.5% | 2026-04-15, Balance as of period end |
| 2023-12-31 | $2.68M | +257.9% | 2025-04-11, Balance as of period end |
| 2022-12-31 | $749.1K | +34.7% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $556.0K | +274.9% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $148.3K | -71.3% | 2022-03-31, Balance as of period end |
| 2019-12-31 | $517.4K | +184.7% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $181.8K | -58.5% | 2020-03-25, Balance as of period end |
| 2017-12-31 | $438.4K | +503.1% | 2019-04-01, Balance as of period end |
| 2016-12-31 | $72.7K | -81.9% | 2018-07-13, Balance as of period end |
| 2015-12-31 | $402.1K | -11.8% | 2017-04-11, Balance as of period end |
| 2014-12-31 | $455.8K | +339.9% | 2016-03-30, Balance as of period end |
| 2013-12-31 | $103.6K | n/a | 2015-03-23, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Q/C Technologies, Inc. (QCLS) | 2025-12-31 | $987.0K | +470.0% |
| Achieve Life Sciences, Inc. (ACHV) | 2025-12-31 | $20.93M | +64.1% |
| Immucell Corp (ICCC) | 2025-12-31 | $3.81M | +1.3% |
| Anbio Biotechnology (NNNN) | 2025-12-31 | $7.77M | -34.0% |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | $11.58M | +34.1% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $5.91M | +59.4% |
| Cardio Diagnostics Holdings, Inc. (CDIO) | 2025-12-31 | $0 | n/a |
| Volitionrx Ltd (VNRX) | 2025-12-31 | $1.12M | -65.8% |
| Biomerica Inc (BMRA) | 2026-05-31 | $1.31M | -45.5% |
Compare QCLS, ACHV, ICCC, NNNN side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗